BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 9205747)

  • 1. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastroprotective properties of ebrotidine. A review.
    Slomiany BL; Piotrowski J; Slomiany A
    Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
    Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility of Helicobacter pylori to antimicrobial agents: effect of ebrotidine and ranitidine.
    Piotrowski J; Piotrowski E; Slomiany A; Slomiany BL
    J Physiol Pharmacol; 1995 Dec; 46(4):463-9. PubMed ID: 8770790
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro anti-Helicobacter pylori activity of ebrotidine.
    Palacín C; Tarragó C; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):471-4. PubMed ID: 9205746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Helicobacter pylori urease activity by ebrotidine.
    Piotrowski J; Slomiany A; Slomiany BL
    Biochem Mol Biol Int; 1995 Oct; 37(2):247-53. PubMed ID: 8673007
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of ebrotidine on gastric mucosal inflammatory responses to Helicobacter pylori lipopolysaccharide.
    Slomiany BL; Piotrowski J; Slomiany A
    J Physiol Pharmacol; 1999 Sep; 50(3):391-404. PubMed ID: 10574469
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
    Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Helicobacter pylori aggregating activity of gastric mucin with ulcer healing by ebrotidine.
    Piotrowski J; Majka J; Piotrowski E; Murty VL; Gabryelewicz A; Slomiany A; Slomiany BL
    Biochem Mol Biol Int; 1994 Nov; 34(5):875-81. PubMed ID: 7535617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
    Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Lipopolysaccharide a virulence factor of Helicobacter pylori: effect of antiulcer agents.
    Piotrowski J
    J Physiol Pharmacol; 1998 Mar; 49(1):3-24. PubMed ID: 9594407
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of gastric mucosal laminin receptor by Helicobacter pylori lipopolysaccharide: effect of ebrotidine.
    Piotrowski J; Morita M; Slomiany A; Slomiany BL
    Biochem Int; 1992 Jun; 27(1):131-8. PubMed ID: 1385705
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Studies on the protective effect of ebrotidine on experimental ulcers induced by non-steroidal anti-inflammatory drugs in healthy volunteers.
    Puscas I; Puscas C; Coltau M; Torres J; Márquez M; Herrero E; Fillat O; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):565-8. PubMed ID: 9205766
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Study on the increment of the amount of gastric mucus in rats after repeated-dose administration of ebrotidine.
    Romero A; Villamayor F; Palop D; Falcó J; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):455-8. PubMed ID: 9205743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Involvement of endogenous nitric oxide and sulfhydryl compounds in ebrotidine-induced gastroprotection.
    Palop D; Conejo L; Sacristán A; Ortiz JA
    Arzneimittelforschung; 1997 Apr; 47(4A):468-71. PubMed ID: 9205745
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroprotective agents in mucosal defense against Helicobacter pylori.
    Slomiany BL; Murty VL; Piotrowski J; Slomiany A
    Gen Pharmacol; 1994 Sep; 25(5):833-41. PubMed ID: 7835626
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mechanism of Helicobacter pylori pathogenesis: focus on mucus.
    Slomiany BL; Slomiany A
    J Clin Gastroenterol; 1992; 14 Suppl 1():S114-21. PubMed ID: 1378466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of gastric somatostatin receptor inhibition by Helicobacter pylori lipopolysaccharide with ebrotidine and sulglycotide.
    Piotrowski J; Skrodzka D; Slomiany A; Slomiany BL
    Gen Pharmacol; 1997 May; 28(5):705-8. PubMed ID: 9184806
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
    Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
    J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Up-regulation of endothelin-1 in gastric mucosal inflammatory responses to Helicobacter pylori Lipopolysaccharide: effect of omeprazole and sucralfate.
    Slomiany BL; Piotrowski J; Slomiany A
    J Physiol Pharmacol; 2000 Jun; 51(2):179-92. PubMed ID: 10898092
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.